#USA #San Francisco #Securities Fraud #Hagens Berman #CVRx Inc.

Hagens Berman Launches Investigation into CVRx Inc.

In light of a staggering 59% decline in its stock price, Hagens Berman, a prominent national securities law firm, is probing into the activities of CVRx Inc. (NASDAQ: CVRX). The investigation comes after recent alarming disclosures including a civil investigative demand from the U.S. Department of Justice (DOJ), a drastic reduction in revenue projections, and significant disruption within the company's sales force.

Background of CVRx Inc.

CVRx Inc., primarily known for its Barostim device—an FDA-approved implantable neuromodulation product aimed at improving heart failure symptoms—has long claimed to target a significant market opportunity estimated at $10.5 billion. The company had previously reassured investors about its strategic growth backed by a fully transformed sales force, yet recent developments have contradicted those optimistic assertions.

Catalysts for Investigation

On May 14, 2026, CVRx received a civil investigative demand from the DOJ, suggesting a deep dive into whether the company was involved in submitting false claims related to its marketing initiatives for Barostim or engaging in inappropriate financial practices such as paying kickbacks to healthcare providers. This demand has ignited concerns about CVRx's previous assurances and its compliance with federal securities laws.

Financially, CVRx has faced severe challenges; in August, the company lowered its revenue forecasts for 2026 and reported critical issues with its sales force. Notably, CVRx disclosed stagnation in sales territory growth amid escalating turnover rates, coupled with problematic onboarding processes for new staff. Furthermore, the approval rate from its primary Medicare Advantage payer, which had previously seen an 80% approval rate for prior authorizations, plummeted to just 25%. This shocking deficit added more strain on the unsuspecting investors.

On August 6, 2026—following these unsettling revelations—CVRx's stock witnessed a dramatic fall. Just days later, the company notably terminated its Chief Revenue Officer, Robert John, sparking speculation about potential internal turmoil.

Investigation Focus

Reed Kathrein, a partner at Hagens Berman leading the investigation, stated, "We are delving into any potential connections between the DOJ's civil investigative demand and the abrupt firing of the Chief Revenue Officer. Additionally, we are scrutinizing whether CVRx misled investors regarding its sales performance and reimbursement rates from Medicare Advantage providers."

The firm urges investors who have suffered significant losses from their investments in CVRx to come forward and evaluate their legal options for recovery. Whistleblowers privy to confidential information pertinent to CVRx's operations are also invited to contribute to the investigation. Individuals providing original information could be eligible for rewards under the SEC's Whistleblower program, potentially securing up to 30% of any successful recovery.

Conclusion

As the investigation unfolds, stakeholders are encouraged to remain vigilant and informed. Hagens Berman's reputation as a leading firm in shareholder rights offers hope for investors seeking justice amidst corporate misconduct. For more information regarding the investigation or to submit any necessary details, investors are advised to visit www.hbsslaw.com/cvrx or directly contact the firm at 844-916-0895 (Partner Reed Kathrein).

Hagens Berman stands firm in its mission to hold corporations accountable, having successfully recovered over $2.9 billion for clients in similar cases. For ongoing updates, follow Hagens Berman on their social media platforms.